No abstract

The development of brigatinib (BGB) is the annexation of a phosphorous-containing dimethyl phosphine oxide (DMPO) group. This DMPO group on the aniline at C4 in the structure has the selective affinity with anaplastic lymphoma kinase (ALK) inhibitor that exhibits superior inhibitory effects against harboring Nonñsmall cell lung cancers (NSCLCs) (1, 2). Lung cancer is the predominant cause of mortality, tobacco comprising 6000 components damaged the DNA and accountable for 90% of lung cancer (3). Brigatinib chemotherapeutic agent used in the treatment of different types of solid tumours especially for NSLC showed 12-folds greater potency (IC 50 ; 10 nmol/L) against all 17 secondary ALK mutants tested across a panel of ALK + cell lines. BGB maintained a high degree of inhibitory activity over more than 250 kinases compared with crizotinib and ceritinib, alectinib first and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (4, 5). In recent past, BGB was approved by US-FDA as an anticancer moiety, under fast approval based on tumor response and duration followed by its promotion as ALUNBRIG TM tablets in two strengths of 30 mg and 90 mg. BGB has the molecular formula C 29 H 39 ClN 7 O 2 P and Mol.wt; 584.102 g/mol (Fig. 1). The Chemical Abstracts Service (CAS) number is 1197953-54-0 with its Medical Subject Heading MeSHAP26113. Its physicochemical properties include off-white